Edwards Lifesciences Corporation $EW Stock Position Cut by Armistice Capital LLC

Key Points

• Armistice Capital LLC significantly reduced its holdings in Edwards Lifesciences Corporation by 62.9%, selling 106,834 shares, leaving them with 62,995 shares valued at approximately $4.57 million.
• Insider transactions included the sale of 8,950 shares by Larry L. Wood, representing a 4.15% decrease in his ownership, while VP Daniel J. Lippis sold 4,114 shares, reflecting a 15.75% decrease in his stake.
• Analyst ratings for Edwards Lifesciences show a consensus of "Moderate Buy" with a target price of $85.90, with some upgrades indicating growing investor confidence in the company's future performance.

Armistice Capital LLC cut its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 62.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,995 shares of the medical research company's stock after selling 106,834 shares during the period. Armistice Capital LLC's holdings in Edwards Lifesciences were worth $4,566,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $49,038,000. Dynamic Advisor Solutions LLC raised its holdings in Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after acquiring an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after acquiring an additional 9,188 shares in the last quarter. Finally, United Asset Strategies Inc. increased its stake in Edwards Lifesciences by 10.4% during the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock valued at $13,450,000 after purchasing an additional 17,412 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on EW shares. Citigroup reiterated a "buy" rating and set a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Wells Fargo & Company boosted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.07 during trading on Friday, hitting $80.89. 2,283,330 shares of the stock were exchanged, compared to its average volume of 3,558,037. The stock's fifty day moving average is $78.77 and its 200 day moving average is $75.21. The stock has a market cap of $47.49 billion, a PE ratio of 11.64, a P/E/G ratio of 3.91 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock valued at $1,698,844 in the last quarter. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.